[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Teclison Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":101},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100416347","phase-2-tate-and-pembrolizumab-mk3475-in-mcrc-and-nsclc-100416347",false,"NCT04701476","TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab","Inclusion Criteria:\n\n* Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations\n* mCRC progressed on at least two lines of standard chemotherapy; or\n* NSCLC progressed on chemotherapy and an immune checkpoint inhibitor\n* Measurable disease\n* ECOG 0-1\n* At least 4 weeks from prior chemotherapy and free from chemo-related toxicity\n* Adequate organ function\n\nExclusion Criteria:\n\n* Prior organ transplantation\n* Liver metastasis more than 50%\n* Oxygen saturation less than 92% in room air\n* Prior autoimmune disorder\n* CNS metastasis\n* Major GI bleeding in the last 2 months","ALL","18 Years",{"count":19,"type":20},110,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.",[26],"Colorectal Cancer; Lung Cancer",[28,29,30,31,32],"colorectal cancer","NSCLC","pembrolizumab","tirapazamine","Liver metastasis","RECRUITING","2026-04-15",{"date":36,"type":37},"2026-04-16","ACTUAL",{"date":39,"type":37},"2021-05-20",{"date":41,"type":20},"2027-09-30",{"name":43,"class":44},"Teclison Ltd.","INDUSTRY",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":5},"100305718","phase-2-combination-of-tate-and-pd-1-inhibitor-in-liver-cancer-100305718","NCT03259867","Combination of TATE and PD-1 Inhibitor in Liver Cancer","Phase IIA Single-Arm Study of Treatment of Patients With Advanced Liver Cancer With a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody","TATE-PD1","1. Patients with a confirmed diagnosis of (1) advanced HCC or (2) metastatic gastric cancer.\n2. Patients between ages 18 and 80\n3. If HCC patients, they should have progressive disease (PD) on an immune therapy for advanced HCC. For patients with metastatic gastric cancer, they should have failed at least one line of systemic chemotherapy and an immune checkpoint inhibitor.\n4. Patients with liver tumor lesions with at least one with a diameter of 2 cm or bigger, which is amendable for (super-)selective TATE as the target lesion.\n5. ECOG score 2 or less\n6. Child-Pugh scores 5-7 for HCC patients\n7. All prior chemotherapy at least 4 weeks prior to study treatment. Immunotherapy not subject to this limitation.\n8. No major GI bleeding in the prior 2 months.\n\n8\\. Hgb\\>=8, platelet \\>= 50,000, Cr =\\\u003C 2, AST and ALT \\\u003C 10 X ULN, t-Bilirubin \\\u003C 3, 9. Patients with a history of major autoimmune disorders excluded.","80 Years",{"count":55,"type":20},54,[23],"This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.",[59,60],"Hepatocellular Carcinoma","Gastric Cancer",[62,63,64,65],"Hepatocellular carcinoma","Immune checkpoint inhibitor","Gastric cancer","Progression",{"date":36,"type":37},{"date":68,"type":37},"2017-07-01",{"date":70,"type":20},"2027-06-30",{"name":43,"class":44},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100222543","phase-1-dose-defining-study-of-tirapazamine-combined-with-embolization-in-liver-cancer-100222543","NCT02174549","Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer","Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer","Inclusion Criteria:\n\n1. Patients with well-differentiated NET and liver-dominant metastatic disease with intrahepatic disease progression, regardless of primary tumor origin or tumor functional status. Patients may have extrahepatic lesions as long as the majority of the disease burden is intrahepatic.\n2. No limitation in hepatic lesion tumor size or number but the total volume of liver tumors cannot exceed 50% of the liver volume.\n3. Patients are allowed to have prior US Food and Drug Administration (FDA)-approved treatments, including systemic therapies, surgery, ablation, or transarterial therapies for the metastatic NET.\n4. Age 20 or higher, ECOG functional status 0-1, and with no known major cardiac, pulmonary, or renal dysfunction.\n5. Are candidates for TAE or TACE and without portal vein occlusion per treating interventional radiologists.\n6. ANC no less than 1000 \u002FμL. Hemoglobin ≥ 9 gm\u002FdL. Platelets no less than 50,000 \u002FμL. Creatinine no more than 2.0 mg\u002FdL. AST, ALT no more than 5X upper limit of normal. Bilirubin no more than 2.5 mg\u002Fdl. PT prolongation ≤ 4 sec above upper limit of normal.\n7. Woman of child-bearing potential (WOCBP) should use highly effective contraception during trial participation and for 6 months after the last dose of tirapazamine and men who are partners with WOCBP should use highly effective contraception, including barrier contraception, during trial participation and for 3 months after the last dose of tirapazamine.","20 Years","99 Years",{"count":82,"type":20},25,[84,23],"PHASE1","This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4 nodules are eligible. Tirapazamine will be given by intra-arterial injection before embolization. Treatment effect is evaluated by MRI based on mRECIST criteria. Repeat treatment is necessary only if disease progression. Dose escalation cohort has been completed. Expansion cohort is open for metastatic liver dominant neuroendocrine tumor.",[59,87,88],"Gastrointestinal Cancer Metastatic","Neuroendocrine Tumors",[90,91,92],"Hypoxia","Embolization","Tirapazamine",{"date":94,"type":37},"2026-04-20",{"date":96,"type":4},"2014-09",{"date":98,"type":20},"2028-09-30",{"name":43,"class":44},2,""]